Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechBNR +3.06%60 EV-to-OCF is -7.96 as of Aug. 18, 2026. GuruFocus rates BNR with a GF Score™ of 60/100 and a GF Value™ of $7.45 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 75.94% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Burning Rock Biotech's Enterprise Value is $38.67 Mil.
Burning Rock Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.86 Mil. Therefore, Burning Rock Biotech's EV-to-OCF for today is -7.96.
The historical rank and industry rank for Burning Rock Biotech's EV-to-OCF or its related term are showing as below:
BNR'
s EV-to-OCF Range Over the Past 10 Years
Min: -577.67 Med: -2.93 Max: 3.55
Current: -7.96
During the past 9 years, the highest EV-to-OCF of Burning Rock Biotech was 3.55. The lowest was -577.67. And the median was -2.93.
BNR's EV-to-OCF is ranked better than 75.94% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.235
vs BNR: -7.96
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Burning Rock Biotech (NAS:BNR) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Burning Rock Biotech's PE Ratio (TTM) for today is calculated as:
Burning Rock Biotech's share price for today is $9.10.
Burning Rock Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Burning Rock Biotech EV-to-OCF Related Terms
Burning Rock Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Burning Rock Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's EV-to-OCF falls into.
Burning Rock Biotech's current Enterprise Value is $38.67 Mil.
Burning Rock Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (BNR) has a EV-to-OCF of -7.96 as of Aug. 18, 2026. According to the industry distribution chart, Burning Rock Biotech ranks #51 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 24.1%.
Is Burning Rock Biotech's EV-to-OCF too high?
Burning Rock Biotech's current EV-to-OCF is -7.96. Based on the distribution chart, Burning Rock Biotech ranks #51 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's EV-to-OCF compare to XGN and PRPO?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #51 out of 212 companies for EV-to-OCF. This places Burning Rock Biotech in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 6.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.24, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current EV-to-OCF is -7.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.45, compared to a current price of $9.10 — trading 22.1% above its estimated fair value. The current EV-to-OCF is -7.96. Burning Rock Biotech's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current EV-to-OCF is -7.96 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $9.10 is trading 22.1% above its estimated GF Value™ of $7.45.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for BNR:
EV-to-OCF: -7.96
GF Value™: $7.45 vs. price of $9.10 (22.1% above fair value)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
60GF Score
Get the complete analysis for BNR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
